Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Cash flows from operating activities:
Net loss	$ (23,317)	$ (18,970)
Adjustments to reconcile net loss to net cash used in operating activities:
Share-based compensation	2,201	2,621
Depreciation	50	0
Acquisition of in-process research and development expense	0	13,117
Changes in the fair value of the warrant liability	0	1,832
Unrealized currency translation	264	0
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	(1,961)	0
Deferred income taxes	208	0
Other assets	(3,074)	0
Accounts payable	(143)	0
Income tax payable	826	0
Accrued expenses	(686)	244
Due to Roivant Sciences Ltd. and Roivant Sciences, Inc.	(1,030)	1,153
Deferred rent	105	3
Net cash used in operating activities	(26,557)	0
Cash flows from investing activities:
Purchase of furniture and equipment	(90)	0
Net cash used in investing activities	(90)	0
Cash flows from financing activities:
Net cash provided by financing activities	0	0
Net change in cash	(26,647)	0
Cash—beginning of period	180,838	0
Cash—end of period	154,191	0
Non-cash investing and financing activities:
Deferred initial public offering costs, unpaid	0	524
Acquisition of in-process research and development	0	13,117
Supplemental disclosure of cash paid:
Income taxes	$ 50	$ 0